Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)

Exclusion Criteria

• •Pregnant or lactating women
• •Active 2nd malignancy or history of another malignancy within 2 years, except:treated, non-melanoma skin cancer,treated breast or cervical carcinoma in situ,or resected T1a or b prostate cancer
• •Chemotherapeutic agents within 4 weeks prior to study
• •High dose CTX with stem cell support within 6 months prior to study
• •Signal transduction inhibitors,or monoclonal antibodies within 4 weeks prior to study
• •Immunotherapy or biological response modifiers within 4 weeks prior to study
• •Systemic hormonal therapy within 4 weeks prior to study
• •Anticoagulant therapy, antiplatelet therapy within 2 weeks prior to study
• •Radiotherapy within 4 weeks prior to study
• •Active autoimmune disorder
• •Central nervous system or leptomeningeal involvement
• •Clinically significant cardiovascular disease
• •Known HIV infection
• •Serious/active infection
• •Surgical procedure within 2 weeks